Myriad Genetics, Inc. (NASDAQ:MYGN) updated its FY18 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $1.00-1.05 for the period, compared to the Thomson Reuters consensus estimate of $1.08. The company issued revenue guidance of $750-770 million, compared to the consensus revenue estimate of $789.30 million.Myriad Genetics also updated its Q1 guidance to $0.19-0.21 EPS.

Several brokerages have recently issued reports on MYGN. BidaskClub lowered shares of Myriad Genetics from a buy rating to a hold rating in a report on Thursday, August 3rd. Zacks Investment Research raised shares of Myriad Genetics from a hold rating to a buy rating and set a $28.00 price target for the company in a report on Monday, July 17th. Piper Jaffray Companies reissued a hold rating and issued a $22.00 price target on shares of Myriad Genetics in a report on Friday, July 14th. Cowen and Company reissued a hold rating and issued a $25.00 price target on shares of Myriad Genetics in a report on Friday, July 14th. Finally, J P Morgan Chase & Co reissued an underweight rating and issued a $16.00 price target on shares of Myriad Genetics in a report on Friday, June 30th. Five analysts have rated the stock with a sell rating, nine have issued a hold rating and two have issued a buy rating to the company’s stock. Myriad Genetics has an average rating of Hold and an average price target of $21.77.

Shares of Myriad Genetics, Inc. (NASDAQ MYGN) traded up 1.35% during trading on Tuesday, reaching $25.55. 1,859,805 shares of the company were exchanged. The firm has a market cap of $1.74 billion, a price-to-earnings ratio of 54.59 and a beta of 0.31. Myriad Genetics, Inc. has a 52-week low of $15.15 and a 52-week high of $31.50. The stock’s 50-day moving average is $24.85 and its 200-day moving average is $20.44.

COPYRIGHT VIOLATION WARNING: “Myriad Genetics, Inc. (NASDAQ:MYGN) Releases FY18 Earnings Guidance” was published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/08/08/myriad-genetics-inc-nasdaqmygn-releases-fy18-earnings-guidance.html.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Earnings History and Estimates for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.